YahooSeptember 28, 2026 at 9:20 AM NY29 Days Ago
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
Investing.com -- MediciNova Inc (NASDAQ:MNOV) shares fell 14.7% in premarket trading Monday following mixed results from a Phase 2 clinical trial evaluating tipelukast (MN-001) for the treatment of nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
